Effects of add-on tipepidine on treatment-resistant depression: an open-label pilot trial

Acta Neuropsychiatr. 2016 Feb;28(1):51-4. doi: 10.1017/neu.2015.43. Epub 2015 Jul 20.

Abstract

Objective: Treatment-resistant depression is a challenging problem in the clinical setting. Tipepidine has been used as a non-narcotic antitussive in Japan since 1959.

Methods: We administered tipepidine to 11 patients with treatment-resistant depression. Tipepidine was given for 8 weeks as an augmentation.

Results: Tipepidine significantly improved depression scores on the Hamilton Rating Scale for depression. Add-on treatment with tipepidine significantly improved scores on the trail making test and Rey auditory verbal learning test. However, no changes were observed in blood concentrations of stress-related hormones (adrenocorticotropic hormone, cortisol, dehydroepiandrosterone sulphate) with tipepidine augmentation.

Conclusion: Tipepidine might be a potential therapeutic drug for treatment-resistant depression.

Keywords: tipepidine; treatment-resistant depression; verbal learning.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antidepressive Agents / administration & dosage*
  • Cognition / drug effects
  • Dehydroepiandrosterone Sulfate / blood
  • Depressive Disorder, Treatment-Resistant / blood
  • Depressive Disorder, Treatment-Resistant / drug therapy*
  • Depressive Disorder, Treatment-Resistant / psychology
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Hydrocortisone / blood
  • Male
  • Memory / drug effects
  • Motor Activity / drug effects
  • Motor Activity / physiology
  • Neuropsychological Tests
  • Pilot Projects
  • Piperidines / administration & dosage*
  • Swimming / physiology

Substances

  • Antidepressive Agents
  • Piperidines
  • tipepidine
  • Dehydroepiandrosterone Sulfate
  • Hydrocortisone